Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour

Journal of Pathology

Volumn 235, Issue 4, 2015, Pages 539-545

  Lee, Jen Chieh ^a   Jeng, Yung Ming ^a   Su, Sheng Yao ^b,c   Wu, Chen Tu ^a   Tsai, Keh Sung ^a   Lee, Cheng Han ^d   Lin, Chung Yen ^b   Carter, Jodi M ^e   Huang, Jenq Wen ^a   Chen, Shu Hwa ^b   Shih, Shyang Rong ^a   Mariño Enríquez, Adrián ^f   Chen, Chih Chi ^a   Folpe, Andrew L ^e   Chang, Yih Leong ^a   Liang, Cher Wei ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b INSTITUTE OF INFORMATION SCIENCE   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d UNIVERSITY OF ALBERTA   (Canada)

^e MAYO CLINIC   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

FGFR1; FN1; Phosphaturic mesenchymal tumour; RNA sequencing; Translocation

Indexed keywords

CHIMERIC PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PROTEIN DERIVATIVE; PROTEIN FN1; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; FGFR1 PROTEIN, HUMAN; FIBRONECTIN; FN1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE FUSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MALE; OLIGOMERIZATION; PHOSPHATURIC MESENCHYMAL TUMOR; PRIORITY JOURNAL; PROTEIN DOMAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SOFT TISSUE TUMOR; WESTERN BLOTTING; AGED; CHEMISTRY; COMPLICATION; CONNECTIVE TISSUE TUMOR; GENETICS; HIGH THROUGHPUT SEQUENCING; HYPOPHOSPHATEMIA, FAMILIAL; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BLOTTING, WESTERN; FEMALE; FIBRONECTINS; GENE FUSION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; HYPOPHOSPHATEMIA, FAMILIAL; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASMS, CONNECTIVE TISSUE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84922647170     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4465     Document Type: Article

References (23)

1. Folpe AL. Phosphaturic mesenchymal tumour. In World Health Organization Classifcation of Tumours of Soft Tissue and Bone, Fletcher CDM, Bridge JA, Hogendoorn PCW, et al (eds). Lyon: IARC Press, 2013; 2.
2. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004; 28: 1-30.
3. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98: 6500-6505.
4. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 1987; 59: 1442-1454.
5. White KE, Larsson TE, Econs MJ. The roles of specifc genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fbroblast growth factor 23. Endocrine Rev 2006; 27: 221-241.
6. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
7. White KE, Cabral JM, Davis SI, et al. Mutations that cause osteoglo-phonic dysplasia defne novel roles for FGFR1 in bone elongation. Am J Hum Genet 2005; 76: 361-367.
8. Parker BC, Engels M, Annala M, et al. Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours. J Pathol 2014; 232: 4-15.
9. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specifc receptor for FGF23. Nature 2006; 444: 770-774.
10. Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010; 41: 461-476.
11. Carter JM, Caron BL, Dogan A, et al. A novel chromogenic in situ hybridization assay for FGF23 mRNA in phospha-turic mesenchymal tumors. Am J Surg Pathol 2014; DOI: 10.1097/PAS.0000000000000290 (in press).
12. Bonin G, Scamps C, Turc-Carel C, et al. Chimeric EWS-FLI1 transcript in a Ewing cell line with a complex t(11;22;14) translocation. Cancer Res 1993; 53: 3655-3657.
13. Liau JY, Lee JC, Wu CT, et al. Dedifferentiated liposarcoma with homologous lipoblastic differentiation: expanding the spectrum to include low-grade tumours. Histopathology 2013; 62: 702-710.
14. Graham RP, Hodge JC, Folpe AL, et al. A cytogenetic analysis of 2 cases of phosphaturic mesenchymal tumor of mixed connective tissue type. Hum Pathol 2012; 43: 1334-1338.
15. Ren H, Tan ZP, Zhu X, et al. Identifcation of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer. Cancer Res 2012; 72: 3312-3323.
16. Shi E, Kan M, Xu J, et al. Control of fbroblast growth factor receptor kinase signal transduction by heterodimerization of combinatorial splice variants. Mol cell biol 1993; 13: 3907-3918.
17. Martin A, Liu S, David V, et al. Bone proteins PHEX and DMP1 regulate fbroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 2011; 25: 2551-2562.
18. Liang G, Chen G, Wei X, et al. Small molecule inhibition of fbroblast growth factor receptors in cancer. Cytokine Growth Factor Rev 2013; 24: 467-475.
19. Fukumoto S. Anti-fbroblast growth factor 23 antibody therapy. Curr Opin Nephrol Hypertens 2014; 23: 346-351.
20. Singh P, Carraher C, Schwarzbauer JE. Assembly of fbronectin extracellular matrix. Annu Rev Cell Dev Biol 2010; 26: 397-419.
21. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009; 25: 1105-1111.
22. Edgren H, Murumagi A, Kangaspeska S, et al. Identifcation of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol 2011; 12: R6.
23. Anders S, McCarthy DJ, Chen Y, et al. Count-based differential expression analysis of RNA sequencing data using R and Biocon-ductor. Nature Protoc 2013; 8: 1765-1786.